PPARG and congenital bilateral aplasia of vas deferens from CFTR mutation: Second, although PPARγ agonists and DPP-4 inhibitors were found to attenuate CAVD independent of glucose control in vitro and vivo, there was lack of large-scale RCTs to further evaluate their efficacy on patients with CAVD.